Thermo Fisher done with big deals ... for now

Acquisition-hungry Thermo Fisher Scientific ($TMO) is taking it down a notch in 2012. CEO Marc Casper tells Bloomberg that after making 5 acquisitions last year, it will use its cash to pay down its $7 billion in debt. Last year, Thermo Fisher made news with its $3.5 billion acquisition of Phadia and $2.1 billion purchase of Dionex. But it may be a little weary after those big buys. Although Casper's company will keep its eye open for deals, he doesn't see larger transactions happening "any time soon." Report

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.